INVION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | -9.09% |
|
-9.09% | 0.00% |
| 05-08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
| 03-05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 21.3M | - | - | - | - | - | |
| 63.85B | - | |||||
| 41.83B | ||||||
| 40.65B | ||||||
| 27.12B | ||||||
| 26.52B |
- Stock Market
- Equities
- IVX Stock
- Charts Invion Limited
- Sector Chart
